Andrx Labs, LLC
Records under this name other than patents Andrx Labs, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,959,946 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,084,058 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Term ended Aug 26, 2026 · From the USPTO record | Term ended | Term ended Aug 26, 2026 | From the USPTO record |
| US 7,785,627 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Term ended Jul 31, 2026 · From the USPTO record | Term ended | Term ended Jul 31, 2026 | From the USPTO record |
| US 9,060,941 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Ended no later than Mar 11, 2025 · Low confidence | Term ended | Ended no later than Mar 11, 2025 | Low confidence |
| US 8,778,395 | Diltiazem controlled release formulation and method of manufacture Lapsed on the fee record Ended Jul 15, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jul 15, 2022 | From the USPTO record |
| US 6,866,866 | Controlled release metformin compositions Formerly held Term ended Term ended Apr 14, 2021 · From the USPTO record | Term ended | Term ended Apr 14, 2021 | From the USPTO record |
| US 6,790,459 | Methods for treating diabetes via administration of controlled release metformin Formerly held Term ended Term ended Mar 17, 2021 · From the USPTO record | Term ended | Term ended Mar 17, 2021 | From the USPTO record |
| US D536,246 | Packaging unit Formerly held Term ended Term ended Feb 6, 2021 · From the USPTO record | Term ended | Term ended Feb 6, 2021 | From the USPTO record |
| US 8,679,534 | HMG-CoA reductase inhibitor extended release formulation Formerly held Term ended Term ended Mar 26, 2020 · From the USPTO record | Term ended | Term ended Mar 26, 2020 | From the USPTO record |
| US 7,919,116 | Controlled release metformin formulations Term ended Term ended Oct 2, 2018 · From the USPTO record | Term ended | Term ended Oct 2, 2018 | From the USPTO record |